{"name":"Alnylam Pharmaceuticals","slug":"alnylam-pharmaceuticals","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":3100000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Amvuttra","genericName":"VUTRISIRAN","slug":"vutrisiran","revenue":1100000000,"yoyGrowth":0,"percentOfTotal":35.5},{"name":"Onpattro","genericName":"PATISIRAN","slug":"patisiran","revenue":700000000,"yoyGrowth":0,"percentOfTotal":22.6},{"name":"Onpattro","genericName":"PATISIRAN SODIUM","slug":"patisiran-sodium","revenue":700000000,"yoyGrowth":0,"percentOfTotal":22.6},{"name":"Givlaari","genericName":"GIVOSIRAN","slug":"givosiran","revenue":400000000,"yoyGrowth":0,"percentOfTotal":12.9},{"name":"Oxlumo","genericName":"LUMASIRAN","slug":"lumasiran","revenue":200000000,"yoyGrowth":0,"percentOfTotal":6.5}],"timeline":[{"date":"2018-01-01","label":"Onpattro first approved","drug":"Onpattro","drugSlug":"patisiran","type":"approval","sentiment":"positive"},{"date":"2018-01-01","label":"Onpattro first approved","drug":"Onpattro","drugSlug":"patisiran-sodium","type":"approval","sentiment":"positive"},{"date":"2019-01-01","label":"Givlaari first approved","drug":"Givlaari","drugSlug":"givosiran","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Oxlumo first approved","drug":"Oxlumo","drugSlug":"lumasiran","type":"approval","sentiment":"positive"},{"date":"2022-01-01","label":"Amvuttra first approved","drug":"Amvuttra","drugSlug":"vutrisiran","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":2500000000,"percentOfTotal":80.6,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Amvuttra","genericName":"VUTRISIRAN","slug":"vutrisiran","indication":"Transthyretin familial amyloid polyneuropathy","status":"marketed","revenue":1100000000},{"name":"Onpattro","genericName":"PATISIRAN","slug":"patisiran","indication":"Polyneuropathy in amyloidosis","status":"marketed","revenue":700000000},{"name":"Onpattro","genericName":"PATISIRAN SODIUM","slug":"patisiran-sodium","indication":"Polyneuropathy in amyloidosis","status":"marketed","revenue":700000000}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":400000000,"percentOfTotal":12.9,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Givlaari","genericName":"GIVOSIRAN","slug":"givosiran","indication":"Hepatic porphyria","status":"marketed","revenue":400000000}]},{"name":"Other","slug":"other","revenue":200000000,"percentOfTotal":6.5,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Oxlumo","genericName":"LUMASIRAN","slug":"lumasiran","indication":"Primary hyperoxaluria, type I","status":"marketed","revenue":200000000}]}],"pipeline":[{"name":"Amvuttra","genericName":"VUTRISIRAN","slug":"vutrisiran","phase":"marketed","mechanism":"Amvuttra works by silencing the production of abnormal TTR protein through RNA interference.","indications":["Transthyretin familial amyloid polyneuropathy"],"catalyst":""},{"name":"Onpattro","genericName":"PATISIRAN","slug":"patisiran","phase":"marketed","mechanism":"Onpattro works by silencing the production of abnormal TTR protein using small interfering RNA.","indications":["Polyneuropathy in amyloidosis","Transthyretin familial amyloid polyneuropathy"],"catalyst":""},{"name":"Onpattro","genericName":"PATISIRAN SODIUM","slug":"patisiran-sodium","phase":"marketed","mechanism":"Onpattro works by silencing the production of abnormal TTR protein through RNA interference.","indications":["Polyneuropathy in amyloidosis","Transthyretin familial amyloid polyneuropathy"],"catalyst":""},{"name":"Givlaari","genericName":"GIVOSIRAN","slug":"givosiran","phase":"marketed","mechanism":"Givlaari works by binding to and silencing the messenger RNA (mRNA) that produces the enzyme aminolevulinate synthase 1 (ALAS1), which is overproduced in patients with hepatic porphyria.","indications":["Hepatic porphyria"],"catalyst":""},{"name":"Oxlumo","genericName":"LUMASIRAN","slug":"lumasiran","phase":"marketed","mechanism":"Oxlumo works by binding to and silencing the mRNA that produces the enzyme Hydroxyacid oxidase 1, which is overactive in patients with Primary hyperoxaluria, type I.","indications":["Primary hyperoxaluria, type I"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQcHN5TlBNSVV6QTVUdU5neGt4bTJqQlAzRkF6UkI0TG13Z2lFZllIN0FmclpzU2ZJZ3YwM2o0TXd3VkxMUmV6N0I5cm43SEFYdkdPSGVKZHA3V0pibEZhWk8xUVhjaVlDcWYtZjJ5S21TZVN3VURPcUNDNnNiaWtQME9QOW9jeFY4bG5rbQ?oc=5","date":"2026-03-06","type":"pipeline","source":"pharmaphorum","summary":"Alnylam bets on Tenaya RNAi tech, and other licensing news - pharmaphorum","headline":"Alnylam bets on Tenaya RNAi tech, and other licensing news","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOMGhMcXlCV2tSOXBhTWlPVF8wZE5FcldlZFp6Mm0tdzFtS0prVFltTHg3MDJWRC1tMmdxYXRhRGFOMXl0Z3hxcnhGN1VxLWx2MjU1dHlIeDNvcGpraFd3eW1LLXJ2SWl3aG84OFBjb0p4WnlPbXZ3Q3FRTmZDaFpuN08wM1dQRHJ2bExBTzllSDFFWTRXYWZROVNHTQ?oc=5","date":"2026-02-12","type":"earnings","source":"BioPharma Dive","summary":"Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor - BioPharma Dive","headline":"Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNNVplS1YxOHdYbmdseXlPQjRRUGZfQnVtdDlUdHg2MkF5d25yeVBPOXdWejZFMXNpZm9KNTBjUHVTa1JmaUliU2ZCQkw5RkJGa2FCOXMydHNacmEyMGZ1OXZUbHFuMWl1ajN5SlFxakhQTUpHandUdDRlVkNwZmNRV3pnSEZ6NFI3LThnY013QXVNY3ZLX0hyOUpOX0JLTHhxRldGREZFZi1nQkU?oc=5","date":"2026-02-08","type":"pipeline","source":"TIKR.com","summary":"Down 34% From All-Time Highs, Can Alnylam Pharmaceuticals Stock Finally Recover In 2026? - TIKR.com","headline":"Down 34% From All-Time Highs, Can Alnylam Pharmaceuticals Stock Finally Recover In 2026?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPUlZ1TUhMZElhVnB3WGgwOTd4Q0ZWTGI2XzlZRDM1ellWSHFiaHczd3dOekJOV3EyYVJxRmdEdVNTVmUyZlp3aFhvYktHeEJqbmdEazhiVHRxUFZrRlpwOVNtZmZUUXRQR2dUVmhNckNpdktuclBPbXFmcHRZT2UwdHpad2c2dGVDZ25lN1o4WGtsY3RHWXFNYms3Q0ZPNUdfU3pYMkg1NEFtWjlmMEg5aUJRQmhSRlhqalJIVl9mT1M3QWtxSVE?oc=5","date":"2026-01-12","type":"pipeline","source":"Benzinga","summary":"What's Going On With Alnylam Pharma Stock Monday? - Alnylam Pharmaceuticals (NASDAQ:ALNY) - Benzinga","headline":"What's Going On With Alnylam Pharma Stock Monday? - Alnylam Pharmaceuticals (NASDAQ:ALNY)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOLVlWRUNYR2J1YlYzenFiYlBlSHZJYlFFVXRKZEZKNVhmdThUMGhBNHdtUDNORHc5UnJOa0xIN0lGVE9TcTFfN3AtNjk1S0hocUROQ0dTcWxzU1p4Qm9iYVZWMGlxVVBvblhUZjNHT2lNOTBTU1hLcUlKck9pdi1mc1ZrQzdNX2JlQ1BpenFsR1FtZGJLWEZQSk9VS1NHd1E2d3EzMnBLRzA1eGI2c0lTelRSVmF0ODg?oc=5","date":"2025-12-17","type":"pipeline","source":"Fierce Pharma","summary":"Alnylam lays out $250M to equip flagship facility with cutting-edge siRNA production tech - Fierce Pharma","headline":"Alnylam lays out $250M to equip flagship facility with cutting-edge siRNA production tech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5qMVRFMm1mdkdBQ2xMTW5sYTZRWVYydDFiSzE0blV2Ukd2bE1OaExrQURMWkE3R2RvS00tanhEbXZsRm5QaDE1U3pWdmJFSVJTMEV3?oc=5","date":"2025-12-17","type":"pipeline","source":"FirstWord Pharma","summary":"Alnylam pours $250M to expand RNAi manufacturing in Massachusetts - FirstWord Pharma","headline":"Alnylam pours $250M to expand RNAi manufacturing in Massachusetts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPc1JRU0lSS05Qc1ctaE9fWU9hVzMtalp4emUtRGVCOHNrdkRhenJISnBBMTRWbzJaR2lCNm85T1FJVG5pQjhDa1ZuXzQ2Y2dOZ2syZlJJelRJdUZhZk1Mb1FhU2JhMHF6bE9nR3hKU2Fod0NRd3RoY2NxZXZnMFlVYmJUTHZxYkgxOXRnS2diZWFlellMTFBqQnZUeXA2dDg?oc=5","date":"2025-11-13","type":"pipeline","source":"Pharma Voice","summary":"RNAi looked doomed to fail — until Alnylam’s science chief found a way - Pharma Voice","headline":"RNAi looked doomed to fail — until Alnylam’s science chief found a way","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNRDBoSG45S3JNT1VZQTRwVHdUc09YdXJ5ZDQ0WjdhMHBkd0pSenZfaWxUQjFWZXR2V1NMdGFFaUN0QzlyUmtUdVVwLXZZdTJYWS1lanI0Y2Y5LUZCUG9UOFExYVV2TGpreGF2OS1IM3lvM0NzcGtCdjlRY25jNS1vS0tTbmk0TXYzVTMtbUdIUktfSnplXzBNMmFKd0ZNaWVuRFhyVm14QU03cEtWbWZrekZ0WkNiM2tyQ1Rj?oc=5","date":"2025-10-31","type":"earnings","source":"Seeking Alpha","summary":"Alnylam Pharmaceuticals: Q3 Earnings Review - A Sensational Year Reaches Its Peak (ALNY) - Seeking Alpha","headline":"Alnylam Pharmaceuticals: Q3 Earnings Review - A Sensational Year Reaches Its Peak (ALNY)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQN3F4ejF4OUNINTd5YnRhTHZmc1hZQTVJcFpWeUJiYnhnNG0tRjBuNUlIUTgxbnI5X0xuUTNscGQyaHV1bFg1bWoyU1E1WXBjOEtRLXVadS13QmJvakpDZnVxUWgyZjgwQmZCU2NLWUNiMHNjSHQxVWVNWmk1bWxlQVR5d1o2MDJfa2tYbjdfUlJSeTI1WVZ3YkdLOTh6cGVQTUNheVNFLTFWQ05kT21fWEdRR0VUVlF2RUE?oc=5","date":"2025-10-31","type":"pipeline","source":"The Pharma Letter","summary":"Top 20 biopharma firms see market cap rise as UCB and Alnylam lead the way | Pharmaceutical | The Pharmaletter - The Pharma Letter","headline":"Top 20 biopharma firms see market cap rise as UCB and Alnylam lead the way | Pharmaceutical | The Pharmaletter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxQSnNJSjdoYkRSNTdKeW1CeHRFUDR5X2ZUSlFpdEhoRlFJaEVBUm90V0M3UUFKS3hudl8wMllLejhIUWVlTlA4WlpRamt3U29VT08zOUJ0b2JXclZ1WlE4TGQ3RnI2ZTRPLWNoR1U3eGxqVVozR3U4dXVzQUNwOG5VUG5VLVZKQTJyNmpWOWNUOFVQVTI5RjlSN1l0d3dKWGw0b1FmQ08zbUdKQ0gtSzdRal9fdFAxWWhuazdXOHJudDlCcklyZEtfcm5TTkVScEp5TzNsZ3VIVkNiQQ?oc=5","date":"2025-09-25","type":"pipeline","source":"Inside Precision Medicine","summary":"Alnylam Joins Illumina and NashBio for Faster, More Inclusive Drug Discovery - Inside Precision Medicine","headline":"Alnylam Joins Illumina and NashBio for Faster, More Inclusive Drug Discovery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOR0hnTUt6bEJQSXhKemgxUWlMUURrY3BFRmdRcDJKb3dmTURwaU54d2gyVzg4dWU2NzVWQjZkbWhqczczRWkyNjlDeEdxMnZvRW5sWnpaUzB1a0NIYmFmZVQwQUFwb20yYjFFTEExQ2F2MWppN0hSX3J4Z3RtSW1FakxBZzRUSmRpSEJzM1Flb05Fb3AtUi1rUEhTSndIbHBGLVBGZ184ZklqNGVHaDZUTGFsMnQ3eEs5MUVwMw?oc=5","date":"2025-09-11","type":"pipeline","source":"Bloomberg.com","summary":"BridgeBio Says Pfizer, Alnylam Aren’t Playing Fair in Blockbuster Race - Bloomberg.com","headline":"BridgeBio Says Pfizer, Alnylam Aren’t Playing Fair in Blockbuster Race","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNMFhqSEExUU5sRUNNQ1pIQlZYRGNiak00UWZZczR3ZEpHM0VlbXNWNUZjWWdoNVE3MTdSX2E5NWpjN2tMWnZUMlRRd1c5TDN2U2VubG9aZXZENDRIekdNUFdEZzhxNE92a3lKM1hJUFptT0IzdHJfVnBRcFdfSXhiWkU5WDl2bnZHckE?oc=5","date":"2025-08-07","type":"pipeline","source":"statnews.com","summary":"Alnylam could be the next mega-cap biotech - statnews.com","headline":"Alnylam could be the next mega-cap biotech","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"marketed":5},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}